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FolateAbstract Background: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme
of folate/homocysteine pathway and is essential for DNA synthesis and methylation.MTHFR gene
polymorphisms have been reported as risk factors for congenital defects and several metabolic and
neurological disorders. Several studies have investigated an association between maternal MTHFR
A1298C polymorphism and Down syndrome (DS) child. However, results have been inconclusive.
Aim: A meta-analysis of published case–control studies up to December, 2015 was performed to
investigate this association.
Methods: Electronic databases were searched for case–control studies and odds ratios (ORs)
with 95% conﬁdence intervals (CIs) were estimated to assess the association. Total twenty-one
case–control studies with 2004 cases and 2523 controls were included in the present meta-analysis.
Results: Results of meta-analysis showed a signiﬁcant association between maternal A1298C
polymorphism and DS pregnancy with homozygote model (CC vs. AA: OR= 1.26, 95%
CI = 1.01–1.58, p= 0.04), but no such association was found in any other genetic models (C vs.
A: OR = 1.07, 95% CI = 0.93–1.23, p= 0.32; CC + AC vs. AA: OR= 1.08, 95% CI = 0.96–
1.23, p= 0.18; CC vs. AC+ AA: OR= 1.11, 95% CI = 0.90–1.36, p= 0.30; AC vs. AA:
OR= 1.06, 95% CI = 0.93–1.21, p= 0.34).
Conclusion: Subgroup and sensitivity analysis results showed that this polymorphism is a risk
factor for DS pregnancy in Asian populations but not in Caucasian population as well as in overall
meta-analysis.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ed meta-
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Down syndrome (DS) is the commonest chromosome abnor-
mality in humans, characterized by trisomy 21. It is a major
cause of abortion and fetal mental retardation, with an inci-
dence of 1–2/1000 live birth [1]. Advanced maternal age is
the only well-reported risk factor for maternal nondisjunction
[2], while the underlying mechanism remains unexplained.
Numerous studies have suggested an association between DS
and maternal folate pathway gene polymorphism. In 1999,
James et al. [3] were the ﬁrst to propose the hypothesis that
abnormal DNA methylation patterns resulting from aberrant
folate metabolism may increase DNA hypomethylation in cen-
tromeric regions, increasing the risk of trisomy 21 [4]. Folate
plays an important role in genetic material distribution during
cell division, because of its part in the cellular methylation
reactions, which, epigenetically regulate chromosome segrega-
tion [5,6]. 5,10-Methylenetetrahydrofolate reductase
(MTHFR) is a key enzyme of folate pathway and several stud-
ies reported signiﬁcant association between maternal MTHFR
polymorphisms and DS [3,7–10], whereas some others studies
could not ﬁnd any association [11–13].
MTHFR enzyme catalyzes the synthesis of 5-
methylenetetrahydrofolate, which remethylates homocysteine
to methionine. Methionine is the main precursor for S-
adenosylmethionine (SAM), the main methyl donor for
DNA, RNA and protein methylation [1]. Insufﬁcient pericon-
ceptional folic acid intake on one hand and deﬁcient folate
metabolism in mothers and fetuses on the other hand have
been acknowledged as risk factors for DS and several other
congenital defects [7,14,15]. It has been suggested that genetic
predisposition to impaired folate metabolism in mothers could
promote DNA hypomethylation and meiotic nondisjunction
resulting in trisomy 21 [7,14].
Several polymorphisms have been reported in MTHFR
gene, out of which C677T and A1298C are clinically important
[16,17]. C677T polymorphism makes MTHFR enzyme ther-Please cite this article in press as: Rai V et al., Null association of maternal MTHF
analysis, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.04molabile. A cytosine to thymine nucleotide substitution at
677 position (C677T) reduces MTHFR enzyme activity and
increases plasma homocysteine concentration [16,18,19]. The
second polymorphism A1298C involving alanine to cytosine
nucleotide substitution inMTHFR gene has also been reported
to reduce enzyme activity [17]. Mutant allele (C) frequency dif-
fers greatly in various ethnic groups of the world. The preva-
lence of the A1298C homozygote variant (CC) ranges from
7% to 12% in the White populations of North America and
Europe. Lower frequencies have been reported in Hispanics
(4–5%), and Asian populations (1–4%) [20,21]. Several studies
have been conducted and demonstrated MTHFR polymor-
phism as a risk factor for congenital defects like NTD [22], oral
clefts [23], congenital heart defects [24], adult disease condi-
tions like cardiovascular and cerebrovascular diseases [20].
The present meta-analysis was carried out to assess the associ-
ation of maternalMTHFR A1298C polymorphism with Down
syndrome pregnancy.2. Method
2.1. Selection of studies
Studies were identiﬁed by a search of PubMed, Google Scho-
lar, Elsevier, and Springer Link databases up to July, 2015.
The following terms were used: ‘methylenetetrahydrofolate
reductase’, ‘MTHFR’, ‘A1298C’, and ‘Down syndrome’ to
identify eligible articles for meta-analysis. The distribution of
the genotypes in the control group was tested for the Hardy–
Weinberg equilibrium (HWE).
2.2. Inclusion and exclusion criteria
Included studies had to meet the following criteria (i) study
should be a case–control association study, (ii) study
should have reported the genotypes of MTHFR A1298CR A1298C polymorphism with Down syndrome pregnancy: An updated meta-
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Table 1 Distributions of MTHFR A1298C genotypes and allele number for cases and controls.
Study Ethnicity Total number of cases Total number of
controls
Genotype Allele HWE (p)
AA AC CC A C
Case Control Case Control Case Control Case Control Case Control
Bosco et al. (2003) Caucasian 63 72 88 100 38 44 NA
Boduroglu et al. (2004) Caucasian 152 91 44 21 97 60 11 10 185 102 119 80 0.001*
Acacio et al. (2005) Caucasian 70 88 2 6 37 32 30 50 41 44 97 132 0.77
Chango et al. (2005) Caucasian 197 119 59 52 49 56 11 12 167 160 71 80 0.58
da Silva et al. (2005) Caucasian 154 158 99 101 49 50 6 7 247 252 61 64 0.79
Rai et al. (2006) Asian 89 70 28 28 39 37 22 5 95 93 83 47 0.12
Scala et al. (2006) Caucasian 94 264 38 128 39 108 17 25 115 364 73 158 0.74
Biselli et al. (2008) Caucasian 72 194 40 108 27 74 5 12 107 290 37 98 0.88
Martinez-Frias et al. (2008) Caucasian 146 188 76 91 57 78 13 19 209 260 83 116 0.7
Meguid et al. (2008) Caucasian 42 48 8 18 20 29 14 1 36 65 48 31 0.008*
Santos-Rebooucas et al.
(2008)
Caucasian 103 108 58 57 40 49 5 2 156 163 50 53 0.01*
Brandalize et al. (2009) Caucasian 239 197 143 113 84 76 12 8 370 302 108 92 0.27
Cyrill et al. (2009) Asian 36 60 14 26 19 21 3 13 47 73 25 47 0.03*
Coppede et al. (2010) Caucasian 29 32 14 13 15 19 0 0 43 45 15 19 0.01*
Vranekovic et al. (2010) Caucasian 111 141 48 63 56 68 7 10 152 194 70 88 0.14
Bozovic et al. (2011) Caucasian 107 221 55 101 52 98 5 22 162 300 62 142 0.8
Sadiq et al. (2011) Asian 53 29 24 10 29 18 0 1 77 38 29 20 0.04*
Zampieri et al. (2012) Caucasian 105 183 51 101 48 73 6 9 150 275 60 91 0.36
Pandey et al. (2013) Asian 80 100 27 60 31 22 23 17 85 142 77 56 0.0001*
Izci Ay et al. (2015) Caucasian 47 49 16 16 24 23 7 10 56 55 38 43 0.74
Sukla et al. (2015) Asian 151 186 69 104 68 65 14 17 206 273 96 99 0.15
HWE (p) p value for the Hardy–Weinberg equilibrium in control group.
NA= not applicable.
* p values < 0.05 in the exact test for the Hardy–Weinberg equilibrium.
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Table 2 Summary estimates for the odds ratio (OR) ofMTHFR A1298C in various allele/genotype contrasts, the signiﬁcance level (p
value) of heterogeneity test (Q test), and the I2 metric: overall analysis, subgroup analyses.
Genetic contrast Fixed eﬀects OR (95% CI),
p
Random eﬀects OR (95%
CI), p
Heterogeneity p-value (Q
test)
I2
(%)
All Allele contrast (C vs. A) 1.06 (0.97–1.17), 0.15 1.07 (0.93–1.23), 0.32 0.002 52
Dominant (CC + AC vs.
AA)
1.08 (0.96–1.23), 0.18 1.09 (0.93–1.28), 0.26 0.06 34
Homozygote (CC vs. AA) 1.26 (1.01–1.58), 0.04 1.20 (0.85–1.71), 0.28 0.009 48.29
Co-dominant (AC vs. AA) 1.06 (0.93–1.21), 0.34 1.06 (0.92–1.23), 0.38 0.24 16.97
Recessive (AA+ AC vs.
CC)
1.11 (0.90–1.36), 0.30 1.07 (0.78–1.47), 0.64 0.008 48.44
Asian Allele contrast (C vs. A) 1.40 (1.14–1.71), 0.001 1.31 (0.89–1.92), 0.15 0.01 68
Dominant (CC + AC vs.
AA)
1.56 (1.19-2.06), 0.001 1.49 (0.96–2.31), 0.07 0.07 53.87
Homozygote (CC vs. AA) 1.78 (1.15-2.76), 0.009 1.52 (0.64–3.61), 0.34 0.02 64.77
Co-dominant (AC vs. AA) 1.52 (1.13–2.04), 0.005 1.48 (0.94–2.32), 0.08 0.09 50
Recessive (AA+ AC vs.
CC)
1.42 (0.95–2.13), 0.08 1.22 (0.52-2.84), 0.63 0.01 66.87
Caucasian Allele contrast (C vs. A) 0.99 (0.90–1.10), 0.96 1.00 (0.88–1.13), 0.97 0.12 30
Dominant (CC + AC vs.
AA)
0.99 (0.86–1.13), 0.89 0.98 (0.85–1.13), 0.86 0.63 0
Homozygote (CC vs. AA) 1.11 (0.85–1.45), 0.42 1.08 (0.75–1.54), 0.67 0.08 35.57
Co-dominant (AC vs. AA) 0.97 (0.84–1.12), 0.74 0.97 (0.84–1.12), 0.72 0.89 0
Recessive (AA+ AC vs.
CC)
1.02 (0.80–1.29), 0.86 0.99 (0.71–1.38), 0.99 0.68 37.93
Figure 1 Forest plots (random effects) show insigniﬁcant association between MTHFR A1298C polymorphism (C vs. A) and maternal
risk of Down syndrome. Results of individual and summary OR estimates, 95% CI, and weights of each study are shown. Horizontal lines
represent 95% CI, and dotted vertical lines represent the value of the summary OR.
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Maternal MTHFR A1298C polymorphism and Down syndrome 5polymorphism in cases and controls and other information
essential for estimation of odds ratio with 95% conﬁdence
interval (CI), and (iii) study should be published. Following
criteria were used for exclusion of studies (i) only cases studied,
(ii) review articles, case reports and editorials and (iii) studies
that contained duplicate data.
2.3. Data extraction
From each study, the following information was extracted:
ﬁrst author’s family name, journal name, country name, year
of publication, and the number of A1298C genotypes in cases
and controls. The allele numbers were calculated from the cor-
responding genotype distributions.2.4. Meta-analysis
The meta-analysis examined the overall association of mater-
nal C allele as a risk for DS relative to allele A. The association
was measured as odds ratios (OR) with 95% conﬁdence inter-
val (CI). Heterogeneity between studies was tested using the Q-
statistic [25,26] and was quantiﬁed with the I2 metric. I2 takes
values between 0% and 100% with higher values denoting
greater heterogeneity [27,28]. The pooled OR was estimated
using ﬁxed effects (FE) [29] and random effects [30] models.
When there is higher heterogeneity, then the random effectsFigure 2 Forest plots (ﬁxed effects) show signiﬁcant association betw
risk of Down syndrome. Results of individual and summary OR estima
represent 95% CI, and dotted vertical lines represent the value of the
Please cite this article in press as: Rai V et al., Null association of maternal MTHF
analysis, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.04model is preferably adopted [31]. All analyses were performed
using the computer program open meta-analyst [32]. A p value
less than 0.05 was considered statistically signiﬁcant, and all
the p values were two sided.
2.5. Sub-group analysis
The subgroup analysis was performed on the basis of ethnicity
i.e. Asian and Caucasian. The sub-group meta-analysis cannot
be performed by the genotyping method because out of
twenty-one studies, nineteen studies were performed on the
basis of PCR-RFLP and one study each on the basis of
sequencing and Taq Man probe.
2.6. Publication bias
Publication bias was assessed by Egger’s test and visual obser-
vation of funnel plot [33]. p< 0.05 was considered statistically
signiﬁcant publication bias.
3. Results
3.1. Characteristics of included studies
Twenty-one studies were found suitable for inclusion in the
present meta-analysis [9,10,13,19,34–50]. The studies were car-een MTHFR A1298C polymorphism (CC vs. AA) and maternal
tes, 95% CI, and weights of each study are shown. Horizontal lines
summary OR.
R A1298C polymorphism with Down syndrome pregnancy: An updated meta-
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6 V. Rai et al.ried out in India [36,42,48,50], Brazil [9,35,37,40,41,47], Italy
[10,34,43], France [19], Croatia [44,45], Egypt [39], Jordan
[46], Spain [38] and Turkey [13,49]. Details of included
twenty-one studies are summarized in Table 1.
3.2. Statistical details
In all twenty-one studies, total cases were 2004 with AA (913),
AC (880) and CC (211), and controls were 2523 with AA
(1217), AC (1056), and CC (250). In controls genotype percent-
age of AA, AC and CCwas 48.24%, 41.85% and 9.91% respec-
tively. In total cases genotype percentage of AA, AC, and CC
was 45.56%, 43.91% and 10.53% respectively. Frequencies of
AA genotype were the highest in both cases and controls.
Genotypes in control samples of seven studies were not in the
Hardy–Weinberg equilibrium [13,39,40,42,43,46,48] (Table 1).
3.3. Meta-analysis
In allele contrast meta-analysis, maternal mutant C allele did
not show signiﬁcant association with DS in both ﬁxed effects
(OR = 1.06, 95% CI = 0.97–1.17, p= 0.15, Phetero = 0.002,
I2 = 52%) and random effects (OR = 1.07, 95% CI = 0.93–
1.23, p= 0.32) models (Table 2, Fig. 1).
Homozygote (CC vs. AA) meta-analysis showed signiﬁcant
association with DS adopting ﬁxed effects model (OR = 1.26,
95% CI = 1.01–1.58, p= 0.04, Phetero = 0.009, I
2 = 48.29%)Figure 3 Forest plots (ﬁxed effects) show no association betweenMT
of Down syndrome. Results of individual and summary OR estimates
represent 95% CI, and dotted vertical lines represent the value of the
Please cite this article in press as: Rai V et al., Null association of maternal MTHF
analysis, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.04(Fig. 2). Association of mutant heterozygous genotype (AC vs.
AA; co-dominant model) was observed insigniﬁcant with both
ﬁxed (OR= 1.06; 95% CI = 0.93–1.21; p= 0.34;
I2 = 16.97%; Phetero = 0.24) and random (OR= 1.06; 95%
CI = 0.92–1.23; p= 0.38) effects models. Similarly combined
maternal mutant genotypes (CC + AC vs. AA; dominant
model) also did not show any association with DS using both
ﬁxed (OR= 1.08; 95% CI = 0.96–1.23; p= 0.18; I2 = 34%;
Phetero = 0.06) and random (OR= 1.09; 95% CI = 0.93–
1.28; p= 0.26) effects models (Fig. 3; Table 2).
3.4. Subgroup analysis
We also performed sub-group analysis which is based on eth-
nicity. Out of 21 studies included in this meta-analysis, ﬁve
studies were on Asian and 16 were on Caucasian. In Asian
populations, allele contrast meta-analysis showed statistically
insigniﬁcant association with random effects model
(OR = 1.31, 95% CI = 0.89–1.92, p= 0.15) with high hetero-
geneity (I2 = 68%), whereas combined mutant genotypes
showed signiﬁcant association adopting random effects model
(OR = 1.49, 95% CI = 0.96–2.31, p= 0.07, I2 = 53.87%). In
this group heterogeneity between studies was high with the
absence of publication bias (Table 2; Fig. 1).
In Caucasian population, allele contrast meta-analysis
showed no association with ﬁxed effects model (OR = 0.99,
95% CI = 0.90–1.10, p= 0.96, Phetero = 0.12, I
2 = 30%)HFR A1298C polymorphism (CC + AC vs. AA) and maternal risk
, 95% CI, and weights of each study are shown. Horizontal lines
summary OR.
R A1298C polymorphism with Down syndrome pregnancy: An updated meta-
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Maternal MTHFR A1298C polymorphism and Down syndrome 7and combined mutant genotypes also showed no association
with ﬁxed (OR= 0.99, 95% CI = 0.86–1.13, p= 0.89,
Phetero = 0.63, I
2 = 0%) effects models (Table 2; Fig. 1).
3.5. Sensitivity analysis
In allele contrast meta-analysis, sensitivity analysis performed
by exclusion of the studies in which control population was not
in the Hardy–Weinberg equilibrium. In overall analysis, after
exclusion of seven studies [13,39,40,42,43,46,48], heterogeneity
was decreased (I2 = 20.58%, p= 0.23) but odds ratio
remained non-signiﬁcant (OR = 1.04, 95% CI = 0.93–1.15,
p= 0.46). Similar effect was also seen in Caucasian sub-
group meta-analysis, after elimination of studies in which con-Figure 4 Funnel plot of
Please cite this article in press as: Rai V et al., Null association of maternal MTHF
analysis, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.04trol population was not in HWE [13,39,40,43] heterogeneity
was decreased (I2 = 0%) OR remains non-signiﬁcant
(OR = 0.98, 95% CI = 0.87–1.10, p= 0.77). In Asian stud-
ies, control population of three studies [42,46,48] was not in
HWE. After elimination of these three studies heterogeneity
was decreased and OR was increased (OR= 1.42, 95%
CI = 1.08–1.86, p= 0.01; Phetero = 0.30; I
2 = 4.92%).
3.6. Publication bias
Funnel plots were symmetrical and did not show any evi-
dence of publication bias. Results of Egger’s test also sug-
gested the absence of publication bias (p= 0.83) for C vs.
A (Fig. 4).allele contrast model.
R A1298C polymorphism with Down syndrome pregnancy: An updated meta-
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8 V. Rai et al.4. Discussion
The present meta-analysis was designated to evaluate the role
of MTHFR A1298C gene polymorphism in the Down syn-
drome pregnancy. A total of twenty-one studies (with 2004
cases and 2523 controls) were incorporated in this study. In
overall analysis the homozygote model (CC vs. AA) showed
a signiﬁcant association (OR= 1.26; 95% CI: 1.01–1.58;
p= 0.04) while no such association was observed in any other
genetic model. Similarly when sub-group analysis based on
ethnicity was performed no signiﬁcant association was found
in any genetic model.
Several in vivo and in vitro studies have reported that folate
deﬁciency in culture media, or inadequate folate dietary intake,
results in DNA hypomethylation, and abnormal chromosome
segregation [47]. For this reason it has been postulated that
impaired folate/homocysteine metabolism due to genetic poly-
morphisms of folate pathway genes could predispose an indi-
vidual to chromosome damage events and might act as a risk
factor for a DS pregnancy [3]. Since 1999, several case–control
studies have investigated maternal folate pathway gene poly-
morphism as a risk factor for DS offspring and positive asso-
ciation has been observed [3,7,8,10,34,35,51]. MTHFR
variants due to less enzymatic activity lead to hypomethylation
of centromeric DNA, which may be the major cause of misseg-
regation of chromosomes during meiosis and results in trisomy
21. Hassold et al. [2] analyzed polymorphism of MTHFR and
MTRR (methionine synthase reductase) maternal genes in tri-
somy of several chromosomes and compared the distribution
of genotypes to those of control populations and observed a
signiﬁcant increase in the MTHFR polymorphisms in mothers
of trisomy cases. Low or inadequate intake of folic acid is
involved in the disruption of methionine metabolism, because
methylenetetrahydrofolate, the primary form of folate in the
circulation, acts as the carbon donor for homocysteine
remethylation to yield methionine and tetrahydrofolate [52].
Several population-based studies and animal model based
studies have shown that folic acid intake during fetal develop-
ment has a protective effect, resulting in a signiﬁcant reduction
in the occurrence of developmental defects, including neural
tube defects (NTD), congenital heart defects (CHD), limb
defects, and orofacial clefts [20].
Meta-analysis is a powerful tool for analyzing cumulative
data of studies where the sample sizes of individual studies
are small and the statistical power is low. During past decade
several meta-analyses were published assessing MTHFR as a
risk factor to various diseases/disorders like NTD [53], cleft
lip and palate [54], congenital heart defects [55], recurrent preg-
nancy loss [56], stroke [57], Down syndrome [58], bipolar dis-
order [59], depression [60] and cancer [61,62]. Four meta-
analyses were published regarding maternal MTHFR poly-
morphism and DS risk [13,58,63,64], out of which only two
meta-analyses investigated maternal MTHFR A1298C poly-
morphism as a risk factor for DS [13,63]. Zintzaras [13] carried
out the ﬁrst meta-analysis of MTHFR A1298C polymorphism
and DS risk, and reported that the allele contrast C versus A
showed signiﬁcant heterogeneity among studies (p= 0.04,
I2 = 56%) and the association was insigniﬁcant: FE
OR= 1.02 (95% CI: 0.81–1.29). A meta-analysis of 10 retro-
spective studies (1007 case mothers and 1318 controls) was car-
ried out by Medica et al. [63] and reported no association (1.06Please cite this article in press as: Rai V et al., Null association of maternal MTHF
analysis, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.04(95% CI: 0.85–1.31)). There are several newly published stud-
ies available but not included in the previous meta-analyses. So
we conducted a comprehensive meta-analysis with the largest
number of studies to date to investigate the possible relation-
ship between maternal MTHFR A1298C polymorphism and
the risk of having DS child.
The present meta-analysis has some limitations also like (i)
crude odds ratio was used, (ii) studies with small sample sizes
[42,43] were included, (iii) meta-analysis was restricted to sin-
gle polymorphism (A1298C), other gene polymorphism of
folate pathway should also be considered, and (iv) except
genetic polymorphism, other important factors such as mater-
nal age, folate intake and homocysteine concentration should
also be considered. The present meta-analysis also had some
strength along with limitations. The main strengths of our
meta-analysis were the absence of publication bias and pooled
number of cases and controls from different studies signiﬁ-
cantly increased the power of the study.
In conclusion, the present study did not support any asso-
ciation between maternal MTHFR gene A1298C polymor-
phism and Down syndrome. However, the present meta-
analysis was based on relatively a small number of studies
and participants, and only one polymorphism was considered,
hence case–control studies that investigate gene-gene and gene-
environment interaction might well elucidate genetics of Down
syndrome.
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